Metra Biosystems expecting to net $30.1 mil. in IPO.
This article was originally published in The Gray Sheet
METRA BIOSYSTEMS' PYRILINKS(II) AND PYRILINKS-D 510(K)s were submitted on May 30 and May 17, respectively, giving the firm three pending 510(k)s for bone resorption assays. According to a recent filing with the Securities and Exchange Commission for an initial public offering, the Mountain View, California-based firm submitted a reworked 510(k) in April for its first bone resorption immunoassay, Pyrilinks, and plans to submit in early June a 510(k) for a fourth product, the Alkaphase-B bone formation assay.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.